SAN DIEGO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that two new bispecific antibodies that target both the CD20 and CD74 receptors on B cells exhibited potent anti-tumor activities against mantle cell (MCL) and other lymphomas in preclinical studies.
